Yejing Shen
YOU?
Author Swipe
View article: Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation
Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation Open
Background and Purpose: Targeted therapy and immunotherapy have led to dramatic change in the treatment of lung cancer, however, the overall 5-year survival rate of lung cancer patients is still suboptimal. It is important to exploit new p…
View article: Additional file 2 of Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation
Additional file 2 of Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation Open
Additional file 1: Supplementary Fig. 1. (A). Gene editing methods in A549 lung cancer cell lines with NRF2 homozygous knockout (The yellow part represents target sequences; the dotted line represents the base sequence of the knockout) (B)…
View article: Loss-of-function mutations in KEAP1 drive lung squamous cell carcinoma progression via KEAP1/NRF2 pathway activation
Loss-of-function mutations in KEAP1 drive lung squamous cell carcinoma progression via KEAP1/NRF2 pathway activation Open
Background and Purpose Targeted therapy has led to dramatic change in the treatment of lung adenocarcinoma, but lung squamous cell carcinoma(LSCC) lacks targeted therapy options. High-frequency somatic mutations in KEAP1/NRF2 (27.9%) have …